Walgreens Boots Alliance stock holds at $11.99 as recent results trim losses
Published on 08/19/2026 at 17:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Walgreens Boots Alliance Inc. (ISIN US9314271019) stock last closed at $11.99 on the Nasdaq, with the shares moving within a day range of $11.90 to $12.11 in the most recent session as of August 19, 2026, according to a recent market-data overview. The same market snapshot shows that investors are weighing a cautious recovery in the company’s earnings profile as revenue edges higher and net losses narrow.
Recent quarters show revenue growth
Per the latest compiled quarterly profit-and-loss table that runs through May 2025, Walgreens Boots Alliance reported total revenue of $38,588 million in the quarter ended February 2025 and $38,980 million in the quarter ended May 2025, both expressed in US dollars. The same quarterly table highlights that revenue increased from $38,588 million to $38,980 million over those two quarters, an absolute gain of $392 million, which corresponds to an average increase of 1.0 percent per quarter.
In the same period, net profit improved from a loss of $2,850 million in the quarter ended February 2025 to a loss of $175 million in the quarter ended May 2025, also denominated in US dollars. That swing of $2,675 million toward breakeven represents what the data provider describes as an average change of 1,530.3 percent per quarter from the starting loss level, underscoring how cost measures and portfolio adjustments have helped to sharply reduce the scale of losses over recent quarters. While the company remained in the red, the magnitude of the loss was dramatically lower in May 2025 than in February 2025.
The same compiled quarterly data set shows that revenue had been trending upward for two consecutive quarters, with the latest figure of $38,980 million in May 2025 above the $38,588 million level reported for February 2025. For investors, this combination of modest top-line growth and a very large reduction in net loss is central to the turnaround narrative around Walgreens Boots Alliance as of mid-2025, forming a fundamental backdrop to the share price behavior seen in August 2026.
Share price context and analyst expectations
According to the same market-data overview, Walgreens Boots Alliance share price today is stated as $11.99 at the close of the market in the latest completed US trading session, with that session’s intraday high and low recorded at $12.11 and $11.90 respectively. The same overview also indicates a consensus target price of $11.93 for the stock, implying a slight downside of 0.5 percent compared with the prevailing $11.99 level.
This small negative gap between the current price and the indicated target suggests that analysts see Walgreens Boots Alliance trading close to what they consider fair value based on the latest available fundamental and sector inputs. With the shares hovering just 0.5 percent above the target price, the market signal as of August 19, 2026 is that expectations for substantial short-term upside are muted and that investors are instead concentrating on execution of the company’s restructuring and cost-efficiency plans, alongside any capital-allocation decisions that could reshape the balance sheet.
The same market-data page notes that recent quarters saw revenue and net profit both improving, with the provider labeling the revenue trajectory as a positive impact and the net-profit pattern as having no direct effect in its scoring framework, even though the absolute change in losses is large. For shareholders, the numerical comparison is straightforward: a reduction in quarterly net loss from $2,850 million to $175 million between February 2025 and May 2025 gives Walgreens Boots Alliance a much smaller earnings hole to climb out of, which in turn can support valuation stability at the current $11.99 price level if that trend is maintained or extended.
Corporate actions and strategic reshaping
Alongside the earnings repair story, Walgreens Boots Alliance has also been active in corporate actions that illustrate how management is reshaping the group’s portfolio. A recent corporate-actions tracker entry states that Walgreens Boots Alliance performed a cash-and-stock merger, under which shareholders of IGMS received $11.45 in cash and one share of the Walgreens Boots Alliance-related instrument for each IGMS share previously held. The corporate actions tracker entry clarifies that fractional shares in this transaction were retained rather than paid out.
This mix of cash and shares in a merger structure highlights how Walgreens Boots Alliance is using its equity as a strategic currency while preserving cash flexibility, an approach that can be important in a period when operating performance is recovering but the balance sheet still reflects prior restructuring charges and investment needs. For investors, the exact terms of the cash-and-stock merger – $11.45 per IGMS share plus one share of the Walgreens Boots Alliance-related security – offer a quantified window into how the company values acquisition targets and how it balances dilution against strategic gain.
More broadly, former management figures from Walgreens Boots Alliance have been commenting on the state of US retail and consumer demand, emphasizing that domestic consumer weakness is real and that retailers need global partners rather than additional regulatory complexity. Recent interviews featuring the company’s former chief executive underline the structural challenges that large pharmacy and convenience chains face, including margin pressure from reimbursement dynamics and competition from both traditional peers and online entrants. These sector-level pressures frame the importance of the revenue and net-loss improvements seen in the February and May 2025 quarters, because they show the company making progress despite a demanding external environment.
Pharmacy services and retail offering
A core pillar of Walgreens Boots Alliance’s business model is its large-scale pharmacy and health-services platform, which combines prescription dispensing with walk-in health offerings and a broad retail assortment. Through its Walgreens and Boots banners, the group operates thousands of stores that offer prescription medications, over-the-counter drugs, health and wellness products, beauty items, and everyday convenience goods, often in locations designed to serve as local community hubs for healthcare and daily shopping needs.
In addition to traditional pharmacy counters, Walgreens Boots Alliance has invested in in-store clinics and partnerships that provide basic primary-care services, vaccinations, and health screenings. These initiatives are designed to increase foot traffic, deepen customer relationships, and capture demand for accessible health services in neighborhoods where patients may face barriers to more complex medical facilities. As the revenue figures for February and May 2025 show, the scale of this footprint supports tens of billions of dollars in quarterly sales, even as the company works to improve profitability and adapt its store network to changing consumer patterns.
On the retail side, the company’s stores increasingly feature curated assortments of personal-care products, beauty brands, and convenience items such as snacks, beverages, and household essentials. This mix aims to keep Walgreens Boots Alliance competitive against both grocery and mass-merchandise chains, leveraging its pharmacy traffic to drive incremental sales in adjacent categories. For investors looking at the $38,980 million revenue number for the quarter ended May 2025, a significant share of that top line is rooted in this omnichannel retail model, which combines physical stores, digital ordering, and in some markets home-delivery options.
Stock level and investor takeaway
Walgreens Boots Alliance stock closed at $11.99 on the Nasdaq in the latest completed session as highlighted by the recent market-data snapshot, with an intraday trading range between $11.90 and $12.11 in that session and a consensus target price of $11.93 that sits just below the market level. The same summary therefore places the shares close to the indicated fair-value band as of August 19, 2026, reflecting modest revenue growth and a steep reduction in net losses in early 2025 alongside ongoing strategic actions such as the cash-and-stock merger transaction.
Fact box
Company: Walgreens Boots Alliance Inc.
ISIN: US9314271019
Ticker: WBA
Exchange: Nasdaq
Price (as of latest completed US session): $11.99 USD
Market cap: data not specified in the available sources
Sector / Industry: Health care - Drug retail
Index membership: S&P 500
